Pharmacogenomics, lipid disorders, and treatment options.

@article{Gryn2014PharmacogenomicsLD,
  title={Pharmacogenomics, lipid disorders, and treatment options.},
  author={Steven E Gryn and Robert A Hegele},
  journal={Clinical pharmacology and therapeutics},
  year={2014},
  volume={96 1},
  pages={
          36-47
        }
}

• Steven E Gryn, Robert A Hegele
• Published 2014 in Clinical pharmacology and therapeutics
• DOI:10.1038/clpt.2014.82

Statins form the backbone of lipid-lowering therapy in the prevention of cardiovascular disease. Numerous studies have evaluated the effect of genomics on the clinical efficacy and adverse effects of statins. Several gene variants that can be linked to either the pharmacokinetics or pharmacodynamics of statins have been identified as potentially important, although there are some discrepant findings among studies. Effect sizes are modest for lipid-lowering efficacy and perhaps somewhat larger… CONTINUE READING

Save to Library

Create Alert

Cite

View on PubMed